keyword
MENU ▼
Read by QxMD icon Read
search

paclitacel

keyword
https://www.readbyqxmd.com/read/20530446/liposomal-cisplatin-dose-escalation-for-determining-the-maximum-tolerated-dose-and-dose-limiting-toxicity-a-phase-i-study
#1
G P Stathopoulos, S K Rigatos, J Stathopoulos
BACKGROUND: The aim of the present trial was to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of liposomal cisplatin (lipoplatin) using nephrotoxicity, gastrointestinal toxicity and myelotoxicity as the main adverse reactions. PATIENTS AND METHODS: Lipoplatin, a liposomal formulation of cisplatin was first tested as monotherapy starting at a dose of 125 mg/m(2) and escalating up to 350 mg/m(2). Lipoplatin was then escalated in combination with paclitacel starting at a dose of 100 mg/m(2) escalating up to 250 mg/m(2) for the former and 100 mg/m(2) escalating up to 175 mg/m(2) for the latter...
April 2010: Anticancer Research
https://www.readbyqxmd.com/read/18499296/a-phase-ii-study-of-carboplatin-and-paclitacel-with-meloxicam
#2
Ryujiro Suzuki, Masashi Yamamoto, Hideo Saka, Hiroyuki Taniguchi, Joe Shindoh, Yoshimasa Tanikawa, Fumio Nomura, Hideo Gonda, Kazuyoshi Imaizumi, Yoshinori Hasegawa, Kaoru Shimokata
BACKGROUND: Cyclooxygenase (COX-2) overexpression is seen in many malignancies including lung cancer. Recent pre-clinical studies have shown that selective COX-2 inhibitors have demonstrated promising results when used with chemotherapy. Based on these observations, we assessed the efficacy and tolerability of the combination chemotherapy consisting of carboplatin and paclitaxel with meloxicam, a selective COX-2 inhibitor. METHODS: Forty-four patients with stage IIIB or IV non-small cell lung cancer (NSCLC), Eastern Cooperative Oncology Group performance status (PS) 0 or 1, who had adequate organ function, were eligible...
January 2009: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/15034952/trastuzumab-in-the-treatment-of-advanced-breast-cancer-our-single-center-experience-and-spotlights-of-the-latest-national-consensus-meeting
#3
REVIEW
Adriana Tomadoni, Diana Lombardo, Raúl Wainstein
Human epidermal growth factor receptor (HER 2) is amplified in 25 to 30% of breast cancer patients and those whose tumors demonstrate HER 2 gene amplification and protein overexpression have an inferior prognosis manifested by shorter disease-free and overall survival. Trastuzumab, the humanized murine anti-HER 2 monoclonal antibody, inhibits tumor growth when used alone and has synergistic and additive effects when used with chemotherapeutic agents (paclitacel-doxorrubicine). At the present time, the accurate diagnostic assessment of HER 2 is essential for appropriate application of the humanized anti HER 2 monoclonal antibody, trastuzumab, for the treatment of patients with metastatic breast cancer...
2004: Medicina
https://www.readbyqxmd.com/read/9132749/-effectiveness-and-hematotoxicity-of-paclitaxel-monotherapy-in-patients-with-advanced-non-small-cell-bronchial-carcinoma-nsclc
#4
M Leutz, P Schlimmer, L Zell, D Ukena, G Sybrecht
In initial studies the dose-limiting toxicity of paclitaxel monotherapy was leukopenia. In these studies, paclitaxel was administered over 24 hrs. The aim of the present phase II clinical trial was to investigate the efficacy and the hematological toxicity of a 3 hr paclitaxel infusion in previously untreated patients with NSCLC. Patients received 4 cycles of a chemotherapy consisting of paclitaxel 225 mg/m2 every three weeks. 30 patients (7 female, 23 male) were enrolled in the study. The characteristics of the patients are as follows: age 64 (47-75 yrs); histology: 19 x squamous cell carcinoma, 11 x adenocarcinoma: 4 x IIIB, 26 x IV; performance status 80 (70-90)...
January 1997: Pneumologie
https://www.readbyqxmd.com/read/8712694/paclitaxel-and-cisplatin-sensitivity-of-ovarian-carcinoma-cell-lines-tested-with-the-96-well-plate-clonogenic-assay
#5
P Engblom, V Rantanen, J Kulmala, S Grènman
Platinum based chemotherapy is the cornerstone of treatment in advanced ovarian carcinoma. Paclitaxel, an unique antimicrotubule agent has shown significant clinical activity in cisplatin-resistant tumours, indicating a lack of cross-resistance. To compare the in vitro sensitivity of ovarian carcinoma to cisplatin and paclitaxel, we tested 7 ovarian carcinoma cell lines with the 96-well plate clonogenic assay. Chemosensitivity was expressed as the IC50 value i.e. the drug concentration causing 50% inhibition of clonogenic survival...
July 1996: Anticancer Research
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"